Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...

Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate ...

A new word is making the rounds in the business press: "anti-involution." In recent years, Chinese companies have built ...

Johnson & Johnson ( JNJ) rose 0.27% to close at $200.12 on Tuesday, marking the seventh consecutive session of gains. An analyst said the company's prospects are helped by strong Q3 results and ...

J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.

Novo Nordisk to lower cash-pay prices for Ozempic and Wegovy to $349 a month; J&J buys Halda Therapeutics for $3.05 billion; Trump attacking health insurers underscores rising tensions around ...

The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology ...

Akzo Nobel NV has agreed to acquire smaller rival paint maker Axalta Coating Systems Ltd in a cross-border deal creating a ...

Johnson & Johnson has announced that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a ...

J&J will acquire Halda Therapeutics in a $3.05B deal, adding prostate cancer therapy HLD-0915 and expanding its oncology ...

Vida Ventures ("Vida"), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and ...

Monetary policy uncertainty dampened US stocks on Monday, with weakness in the heavyweight banking and tech sectors pushing indices to their lowest levels in a month.